ArriVent BioPharma (NASDAQ:AVBP) Hits New 52-Week Low at $14.35

ArriVent BioPharma, Inc. (NASDAQ:AVBP)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as $14.35 and last traded at $15.33, with a volume of 8994 shares traded. The stock had previously closed at $15.30.

Analyst Ratings Changes

Several equities analysts have commented on AVBP shares. Citigroup started coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $30.00 price target on the stock. Jefferies Financial Group started coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $35.00 price target on the stock. Finally, The Goldman Sachs Group started coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They set a “buy” rating and a $27.00 price target on the stock.

ArriVent BioPharma Trading Down 0.6 %

The firm has a 50 day simple moving average of $18.53.

Insider Transactions at ArriVent BioPharma

In related news, Director Orbimed Advisors Llc acquired 444,444 shares of the stock in a transaction dated Tuesday, January 30th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $7,999,992.00. Following the completion of the purchase, the director now owns 1,513,664 shares in the company, valued at approximately $27,245,952. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Orbimed Advisors Llc bought 444,444 shares of ArriVent BioPharma stock in a transaction that occurred on Tuesday, January 30th. The stock was purchased at an average cost of $18.00 per share, with a total value of $7,999,992.00. Following the completion of the transaction, the director now directly owns 1,513,664 shares in the company, valued at $27,245,952. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Hillhouse Investment Managemen bought 555,555 shares of ArriVent BioPharma stock in a transaction that occurred on Tuesday, January 30th. The stock was purchased at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the completion of the transaction, the insider now owns 4,484,672 shares of the company’s stock, valued at $80,724,096. The disclosure for this purchase can be found here.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.